Abstract:BACKGROUND:Hyperinsulinemia, insulin-like growth factor (IGF)-I and -II (IGF-II) are associated with increased risk of endometrial carcinoma. Insulin receptor isoform A (IR-A) is more frequently expressed in endometrial carcinoma than in normal endometrial tissues. To better understand their roles in endometrial carcinoma, we investigated the effects of insulin, IGF-I, and IGF-II in endometrial carcinomas cells with different IR-A expression levels.METHODS:To explore the role of IR-A in mediating the activity of IGF-I, IGF-II, and insulin, we investigate the cellular proliferation of endometrial carcinoma cell lines RL95-2 and RL95-2-IR-A by MTS assays. Then we examined the protein kinase Akt phosphorylation and extracellular signal-regulated kinase (ERK) 1/2 phosphorylation in both cell lines by Western blotting. The effect of IGF-II and AG1024 on cell cycle progression and apoptosis was assessed by flowcytometry. To examine whether the effects of IGFs were mediated by IR-A, we blocked IGF-I receptor (IGF-IR) in both cell lines using AG1024, an IGF-IR-specific inhibitor.RESULTS:IGF-I and IGF-II significantly enhanced proliferation of both cell lines (P < 0.05). By contrast, insulin significantly increased proliferation of RL95-2-IR-A cells only (P < 0.05). IGF-I and IGF-II significantly increased pAkt levels in RL95-2 cells and pERK1/2 levels in RL95-2-IR-A cells (all, P < 0.05). Insulin increased pERK1/2 levels in RL95-2-IR-A cells only (P < 0.05). LY294002 and PD98059 inhibited the specific signaling activities and cellular proliferation. After AG1024 pretreatment, neither IGF-I nor IGF-II affected pAkt levels in RL95-2 cells. IGF-II, but not IGF-I, increased pERK1/2 levels in RL95-2-IR-A cells. After AG1024 pretreatment, the proliferation rate and DNA content corresponding to the S phase increased and apoptosis decreased significantly in IGF-II-treated RL95-2-IR-A cells only (P < 0.05).CONCLUSIONS:The proliferation effect of insulin is mediated by IR-A. When IR-A dominates in a cell line, IGF-II activated cell proliferation mainly through the ERK1/2 pathway. On the other hand, IGF-II activated cell proliferation mainly through the Akt pathway. IR-A can at least partly mediate the proliferative and anti-apoptotic effects of IGF-II through the ERK1/2 pathway.

TET1-GPER-PI3K/AKT Pathway is Involved in Insulin-Driven Endometrial Cancer Cell Proliferation.

Increased Tet1 Expression in Inflammatory Microenvironment of Hyperinsulinemia Enhances the Response of Endometrial Cancer to Estrogen by Epigenetic Modulation of Gper

Igfbp-Rp1 Acts As A Potential Tumor Suppressor Via the Suppression of Erk Signaling Pathway in Endometrial Cancer Cells

Estrogen and insulin synergistically promote endometrial cancer progression via crosstalk between their receptor signaling pathways

Estrogen and insulin synergistically promote type 1 endometrial cancer progression

17β-estradiol protects INS-1 insulinoma cells from mitophagy via G protein-coupled estrogen receptors and the PI3K/Akt signaling pathway

Effects of Insulin, Insulin-Like Growth Factor-I and -II on Proliferation and Intracellular Signaling in Endometrial Carcinoma Cells with Different Expression Levels of Insulin Receptor Isoform A.

Metformin Sensitizes Endometrial Cancer Cells to Progestin by Targeting TET1 to Downregulate Glyoxalase I Expression

Role of Suppressor Encoprotein PTEN in IGF-1 Induced Activation of ERK in Endometrial Carcinoma Cells

TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway

Drp1 Mediates High Glucose-Induced Mitochondrial Dysfunction and Epithelial-Mesenchymal Transition in Endometrial Cancer Cells.

Picropodophyllin Inhibits Type I Endometrial Cancer Cell Proliferation Via Disruption of the PI3K/Akt Pathway.

The Expression and Role of Hybrid Insulin/insulin-Like Growth Factor Receptor Type 1 in Endometrial Carcinoma Cells.

LIN28B induced PCAT5 promotes endometrial cancer progression and glycolysis via IGF2BP3 deubiquitination

Insulin Promotes Proliferation of Pancreatic Ductal Epithelial Cells by Increasing Expression of PLK1 Through PI3K/AKT and NF-κB Pathway.

Metabolic disorders sensitise endometrial carcinoma through endoplasmic reticulum stress

Overexpression of TICRR and PPIF confer poor prognosis in endometrial cancer identified by gene co-expression network analysis

Repression of Endometrial Tumor Growth by Targeting SREBP1 and Lipogenesis

Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer

Proteomic Analysis of Human Endometrial Tissues Reveals the Roles of PI3K/AKT/mTOR Pathway and Tumor Angiogenesis Molecules in the Pathogenesis of Endometrial Cancer

SIRT1 Promotes Endometrial Tumor Growth by Targeting SREBP1 and Lipogenesis.